Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study

International Journal of Cardiology

Volumn 142, Issue 3, 2010, Pages 257-264

  Gensini, G F ^a,b   Gori, A M ^a,b   Dilaghi, B ^a,b   Rostagno, C ^a,b   Gaw, A ^c   Blanco Colio, L M ^d   De Teresa, E ^e,f   Egido, J ^d   Farsang, C ^g   Leiter, L A ^h,i   Martineau, P ^j   Nozza, A ^j   Langer, A ^h,i,k  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e UNIVERSITY OF MÁLAGA   (Spain)

^f Endocrinology and Nutrition Service   (Spain)

^g SEMMELWEIS UNIVERSITY   (Hungary)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j PFIZER INC   (United States)

^k CANADIAN HEART RESEARCH CENTRE   (Canada)

more..

Author keywords

Atorvastatin; C reactive protein (hsCRP); Coronary artery disease; Dyslipidemia; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; AGED; BLOOD; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK FACTOR;

AGED; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS;

EID: 77955756190     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.12.213     Document Type: Article

References (47)

1. G.J. Blake, and P.M. Ridker Novel clinical markers of vascular wall inflammation Circ Res 89 2001 763 771
2. P. Libby, and P.M. Ridker Inflammation and atherosclerosis: role of C-reactive protein in risk assessment Am J Med 116 Suppl 6A 2004 9S 16S
3. V. Fuster, P.R. Moreno, Z.A. Fayad, R. Corti, and J.J. Badimon Atherothrombosis and high-risk plaque: part I: evolving concepts J Am Coll Cardiol 46 2005 937 954
4. J.F. Viles-Gonzalez, V. Fuster, and J.J. Badimon Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences Eur Heart J 25 2004 1197 1207
5. E. Braunwald Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities N Engl J Med 337 1997 1360 1369
6. T.W. Du Clos Function of C-reactive protein Ann Med 32 2000 274 278
7. S. Verma, M.A. Kuliszewski, and S.H. Li, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease Circulation 109 2004 2058 2067
8. S. Verma, S. Li, and M. Badiwala, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein Circulation 105 2002 1890 1896
9. Y.J. Liang, K.G. Shyu, B.W. Wang, and L.P. Lai C-reactive protein activates the nuclear factor-kappaB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells J Mol Cell Cardiol 40 2006 412 420
10. O. Schlager, M. Exner, and W. Mlekusch, et al. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis Stroke 38 2007 1263 1268
11. M.S. Sabatine, D.A. Morrow, and K.A. Jablonski, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease Circulation 115 2007 1528 1536
12. B.M. Everett, T. Kurth, J.E. Buring, and P.M. Ridker The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women J Am Coll Cardiol 48 2006 2235 2242
13. A.S. Wierzbicki, R. Poston, and A. Ferro The lipid and non-lipid effects of statins Pharmacol Ther 99 2003 95 112
14. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 2004 III39 III43
15. I. Jialal, D. Stein, and D. Balis, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 2001 1933 1935
16. M.A. van de Ree, M.V. Huisman, H.M. Princen, A.E. Meinders, and C. Kluft Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus Atherosclerosis 166 2003 129 135
17. S.M. Macin, E.R. Perna, and E.F. Farias, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study Am Heart J 149 2005 451 457
18. J. Bonnet, R. McPherson, and A. Tedgui, et al. Comparative effects of 10-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic Effects) study. Clin Ther 30 12 2008 2298-313
19. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, and E. Braunwald Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) investigators Circulation 100 1999 230 235
20. P. Ridker, N. Rifai, and M. Clearfield, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965
21. P.M. Ridker, C.P. Cannon, and D. Morrow, et al. C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
22. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38
23. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
24. P. Martineau, A. Gaw, and E. de Teresa, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study Atherosclerosis 191 2007 135 146
25. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects J Int Bioethique 15 2004 124 129
26. Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 26 Suppl 1 2003 S5 S20
27. T.A. Miettinen, K. Pyorala, and A.G. Olsson, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) Circulation 96 1997 4211 4218
28. G.C. Flaker, J.W. Warnica, and F.M. Sacks, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events (CARE) investigators J Am Coll Cardiol 34 1999 106 112
29. K. Pyorala, C.M. Ballantyne, and B. Gumbiner, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 27 2004 1735 1740
30. C. Cannon, E. Braunwald, and C. McCabe, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
31. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
32. J.C. Corvol, A. Bouzamondo, and M. Sirol, et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials Arch Intern Med 163 2003 669 676
33. M. Briel, M. Studer, T.R. Glass, and H.C. Bucher Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials Am J Med 117 2004 596 606
34. P. Amarenco, J. Labreuche, P. Lavallee, and P.J. Touboul Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis Stroke 35 2004 2902 2909
35. S. van Wissen, M.D. Trip, and T.J. Smilde, et al. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy Atherosclerosis 165 2002 361 366
36. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, and K.A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517
37. S.M. Kent, P.J. Flaherty, L.C. Coyle, T.T. Markwood, and A.J. Taylor Effect of atorvastatin and pravastatin on serum C-reactive protein Am Heart J 145 2003 e8
38. A.J. Taylor, S.M. Kent, and P.J. Flaherty, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness Circulation 106 2002 2055 2060
39. S. Kinlay, T. Timms, and M. Clark, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia Am J Cardiol 89 2002 1205 1207
40. E. Ordulu, and O. Erdogan Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes Int J Cardiol 128 2008 282 284
41. M. Sugiyama, M. Ohashi, and H. Takase, et al. Effects of atorvastatin on inflammation and oxidative stress Heart Vessels 20 2005 133 136
42. W.F. Riesen, H. Engler, M. Risch, W. Korte, and G. Noseda Short-term effects of atorvastatin on C-reactive protein Eur Heart J 23 2002 794 799
43. M. Albert, E. Danielson, N. Rifai, and P. Ridker Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
44. S. Kinlay, G. Schwartz, and A. Olsson, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study Circulation 108 2003 1560 1566
45. L.C. Correia, A.C. Sposito, and L.C. Passos, et al. Short-term effect of atorvastatin (80 mg) on plasma lipids of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction Am J Cardiol 90 2002 162 164
46. T.A. Pearson, G.A. Mensah, and R.W. Alexander, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
47. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150